[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601089":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":27,"collaborators":7,"id":30,"slug":7,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":7,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":7,"overallStatus":46,"whyStopped":7,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":56},{"fullName":5,"class":6},"Nanjing First Hospital, Nanjing Medical University","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Feng Wang","CONTACT","+8602552271491","fengwangcn@hotmail.com",[15],{"facility":16,"status":7,"city":17,"state":18,"zip":19,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":7},"Nanjing First Hospital","Nanjing","Jingasu","210006","China",{"type":22,"coordinates":23},"Point",[24,25],118.77778,32.06167,{"lat":25,"lon":24},{"type":28,"investigatorFullName":10,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Chief physician","100601089",false,"NCT07105956","Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.","Clinical Application of a Novel Radiolabeled Translocator Protein (TSPO) Targeted Small Molecular Probe in Neuroinflammation Imaging of Alzheimer's Disease.","Inclusion Criteria:\n\n* Volunteer for the trial, with the patient or their legal guardian signing the informed consent form.\n* Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends.\n* The patient is diagnosed with Alzheimer's disease (AD), supported by a positive amyloid PET scan.\n* The patient has completed Tau PET scan.\n\nExclusion Criteria:\n\n* Individuals with a history of allergy to drugs chemically or biologically similar to TSPO, a history of atopy, or currently suffering from allergic diseases.\n* Use of anti-inflammatory drugs, including corticosteroids and immunosuppressants, within the past 14 days, which may interfere with the accuracy of inflammation imaging.\n* Presence of other coexisting neurological diseases, such as stroke, Parkinson's disease, brain tumors, or mental disorders, including depressive disorder and schizophrenia.\n* Severe cardiac, pulmonary, hepatic, or renal dysfunction, or uncontrolled systemic diseases; 5. Presence of metal implants contraindicated for MRI, including but not limited to cardiac pacemakers, artificial heart valves, and metal stents.\n* Claustrophobia or inability to tolerate prolonged examinations.\n* Pregnant women (defined as those with a positive urine pregnancy test) or breastfeeding women.\n* Patients whose physical condition is unsuitable for radioactive tracer-based imaging examinations.\n* Other circumstances deemed unsuitable for participation in the trial by the researcher.","ALL","18 Years","75 Years",{"count":40,"type":41},8,"ESTIMATED","OBSERVATIONAL","Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \\[68Ga\\]-DOTA-HK-011 in neuroinflammation imaging of Alzheimer's disease.",[45],"Alzheimer's Disease (AD)","NOT_YET_RECRUITING","2025-07-30",{"date":49,"type":50},"2025-08-06","ACTUAL",{"date":52,"type":41},"2025-09-01",{"date":54,"type":41},"2026-08-31",{"name":5,"class":6},1]